FDA Approved: TAFINLAR — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA supplemental application for TAFINLAR (dabrafenib) submitted by Novartis Pharmaceuticals Corporation to seek changes to the drug's labeling or indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• TAFINLAR (DABRAFENIB)

Snippet

SUPPL AP for TAFINLAR (DABRAFENIB)